The transcripts of SFRP1, CEP63 and EIF4G2 genes are frequently downregulated in transitional cell carcinomas of the bladder

Oncology

Volumn 69, Issue 6, 2006, Pages 445-454

  Buim, Marcilei E ^a,b   Soares, Fernando A ^b   Sarkis, Álvaro S ^a   Nagai, Maria Aparecida ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b A C CAMARGO CANCER CENTER   (Brazil)

Author keywords

Bladder cancer; CEP63; Differential gene expression; EIF4G2; SFRP1

Indexed keywords

CENTROSOME PROTEIN 63; EUKARYOTIC TRANSLATION INITIATION FACTOR 4 GAMMA 2; PROTEIN; SECRETED FRIZZLED RELATED PROTEIN 1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CARCINOGENESIS; CONTROLLED STUDY; DIFFERENTIAL DISPLAY; DOWN REGULATION; EVOLUTIONARY HOMOLOGY; FEMALE; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE TAGGED SITE; STATISTICAL SIGNIFICANCE; TRANSITIONAL CELL CARCINOMA; UNINDEXED SEQUENCE;

ADULT; AGED; CARCINOMA, TRANSITIONAL CELL; CLONING, MOLECULAR; DNA, COMPLEMENTARY; DNA, NEOPLASM; DOWN-REGULATION; EUKARYOTIC INITIATION FACTOR-4G; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; TRANSCRIPTION, GENETIC; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 32044457901     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000090984     Document Type: Article

References (52)

1. Heney NM: Natural history of superficial bladder cancer. Prognostic features and long-term disease course. Urol Clin North Am 1992;19:429-433.
2. Skinner DG, Stein JP, Lieskovsky G, Skinner EC, Boyd SD, Figueroa A, Jones P, Cote R, Groshen S: 25-year experience in the management of invasive bladder cancer by radical cystectomy. Eur Urol 1998;33(suppl 4):25-26.
3. Bane BL, Rao JY, Hemstreet GP: Pathology and staging of bladder cancer. Semin Oncol 1996;23:546-570.
4. Holmang S: Follow-up of patients with noninvasive and superficially invasive bladder cancer. Semin Urol Oncol 2000;18:273-279.
5. Halachmi S, Madeb R, Kravtsov A, Moskovitz B, Halachmi N, Nativ O: Bladder cancer - Genetic overview. Med Sci Monit 2001;7:164-168.
6. Williams SG, Stein JP: Molecular pathways in bladder cancer. Urol Res 2004;32:373-385.
7. Sanchez-Carbayo M: Recent advances in bladder cancer diagnostics. Clin Biochem 2004;37:562-571.
8. Nicholson BE, Frierson HF, Conaway MR, Seraj JM, Harding MA, Hampton GM, Theodorescu D: Profiling the evolution of human metastatic bladder cancer. Cancer Res 2004;64:7813-7821.
9. Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-159.
10. Finch PW, He X, Kelley MJ, Uren A, Schaudies RP, Popescu NC, Rudikoff S, Aaronson SA, Varmus HE, Rubin JS: Purification and molecular cloning of a secreted, frizzled-related antagonist of Wnt action. Proc Natl Acad Sci USA 1997;94:6770-6775.
11. Rattner A, Hsieh JC, Smallwood PM, Gilbert DJ, Copeland NG, Jenkins NA, Nathans J: A family of secreted proteins contains homology to the cysteine-rich ligand-binding domain of frizzled receptors. Proc Natl Acad Sci USA 1997;94:2859-2863.
12. Polakis P: Wnt signaling and cancer. Genes Dev 2000;14:1837-1851.
13. Wang S, Krinks M, Moos M Jr: Frzb-1, an antagonist of Wnt-1 and Wnt-8, does not block signaling by Wnts-3A, -5A or -11. Biochem Biophys Res Commun 1997;236:502-504.
14. Kawano Y, Kypta R: Secreted antagonists of the Wnt signalling pathway. J Cell Sci 2003;116:2627-2634.
15. Ugolini F, Charafe-Jauffret E, Bardou VJ, Geneix J, Adelaide J, Labat-Moleur F, Penault-Llorca F, Longy M, Jacquemier J, Birnbaum D, Pebusque MJ: WNT pathway and mammary carcinogenesis: loss of expression of candidate tumor suppressor gene SFRP1 in most invasive carcinomas except of the medullary type. Oncogene 2001;20:5810-5817.
16. Caldwell GM, Hones C, Gensberg K, Jan S, Hardy RG, Byrd P, Chughtai S, Wallis Y, Matthews GM, Morton DG: The Wnt antagonist SFRP1 in colorectal tumorigenesis. Cancer Res 2004;64:883-888.
17. To KF, Chan MW, Leung WK, Yu J, Tong JH, Lee TL, Chan FK, Sung JJ: Alterations of frizzled (FzE3) and secreted frizzled related protein (hsFRP) expression in gastric cancer. Life Sci 2001;70:483-489.
18. Wissmann C, Wild PJ, Kaiser S, Roepcke S, Stoehr R, Woenckhaus M, Kristiansen G, Hsieh JC, Hofstaedter F, Hartmann A, Knuechel R, Rosenthal A, Pilarsky C: WIF1, a component of the Wnt pathway, is down-regulated in prostate, breast, lung, and bladder cancer. J Pathol 2003;201:204-212.
19. Stoehr R, Wissmann C, Suzuki H, Knuechel R, Krieg RC, Klopocki E, Dahl E, Wild P, Blaszyk H, Sauter G, Simon R, Schmitt R, Zaak D, Hofstaedter F, Rosenthal A, Baylin SB, Pilarsky C, Hatmann A: Deletions of chromosome 8p and loss of SFRP1 expression are progression markers of papillary bladder cancer. Lab Invest 2004;84:465-478.
20. Suzuki H, Gabrielson E, Chen W, Anbazhagan R, van Engeland M, Weijenberg MP, Herman JG, Baylin SB: A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet 2002;31:141-149.
21. Takada T, Yagi Y, Maekita T, Imura M, Nakagawa S, Tsao SW, Miyamoto K, Yoshino O, Yasugi T, Taketani Y, Ushijima T: Methylation-associated silencing of the Wnt antagonist SFRP1 gene in human ovarian cancers. Cancer Sci 2004;95:741-744.
22. Andersen JS, Wilkinson CJ, Mayor T, Mortensen P, Nigg EA, Mann M: Proteomic characterization of the human centrosome by protein correlation profiling. Nature 2003;426:570-574.
23. Varmark H: Functional role of centrosomes in spindle assembly and organization. J Cell Biochem 2004;91:904-914.
24. Hinchcliffe EH, Miller FJ, Cham M, Khodjakov A, Sluder G: Requirement of a centrosomal activity for cell cycle progression through G1 into S phase. Science 2001;291:1547-1550.
25. Brinkley BR: Managing the centrosome numbers game: from chaos to stability in cancer cell division. Trends Cell Biol 2001;11:18-21.
26. Bomens M: Centrosome composition and microtubule anchoring mechanisms. Curr Opin Cell Biol 2002;14:25-34.
27. Dey P: Aneuploidy and malignancy: an unsolved equation. J Clin Pathol 2004;57:1245-1249.
28. Gagos S, Irminger-Finger I: Chromosome instability in neoplasia: chaotic roots to continuous growth. Int J Biochem Cell Biol 2005;37:1014-1033.
29. Nigg EA: Centrosome aberrations: cause or consequence of cancer progression? Nat Rev Cancer 2002;2:815-825.
30. Raff JW: Centrosomes and cancer: lessons from a TACC. Trends Cell Biol 2002;12:222-225.
31. Zhou H, Kuang J, Zhong L, Kuo WL, Gray JW, Sahin A, Brinkley BR, Sen S: Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet 1998;20:189-193.
32. Takahashi T, Futamura M, Yoshimi N, Sano J, Katada M, Takagi Y, Kimura M, Yoshioka T, Okano Y, Saji S: Centrosomal kinases, HsAIRK1 and HsAIRK3, are overexpressed in primary colorectal cancers. Jpn J Cancer Res 2000;91:1007-1014.
33. Sen S, Zhou H, Zhang RD, Yoon DS, Vakar-Lopez F, Ito S, Jiang F, Johnston D, Grossman HB, Ruifrok AC, Katz RL, Brinkley W, Czerniak B: Amplification/overexpression of a mitotic kinase gene in human bladder cancer. J Natl Cancer Inst 2002;94:1320-1329.
34. Warner SL, Bearss DJ, Han H, Von Hoff DD: Targeting Aurora-2 kinase in cancer. Mol Cancer Ther 2003;2:589-595.
35. Chen HM, Schmeichel KL, Mian IS, Lelievre S, Petersen OW, Bissell MJ: AZU-1: a candidate breast tumor suppressor and biomarker for tumor progression. Mol Biol Cell 2000;11:1357-1367.
36. Calkhoven CF, Muller C, Leutz A: Translational control of gene expression and disease. Trends Mol Med 2002;8:577-583.
37. Pestova TV, Kolupaeva VG, Lomakin IB, Pilipenko EV, Shatsky IN, Agol VI, Hellen CU: Molecular mechanisms of translation initiation in eukaryotes. Proc Natl Acad Sci USA 2001;98:7029-7036.
38. Dever TE: Gene-specific regulation by general translation factors. Cell 2002;108:545-556.
39. Bonnal S, Boutonnet C, Prado-Lourenco L, Vagner S: IRESdb: the Internal Ribosome Entry Site database. Nucleic Acids Res 2003;31:427-428.
40. De Benedetti A, Rhoads RE: Overexpression of eukaryotic protein synthesis initiation factor 4E in HeLa cells results in aberrant growth and morphology. Proc Natl Acad Sci USA 1990;87:8212-8216.
41. Lazaris-Karatzas A, Montine KS, Sonenberg N: Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5′ cap. Nature 1990;345:544-547.
42. De Benedetti A, Harris AL: eIF4E expression in tumors: its possible role in progression of malignancies. Int J Biochem Cell Biol 1999;31:59-72.
43. Crew JP, Fuggle S, Bicknell R, Cranston DW, de Benedetti A, Harris AL: Eukaryotic initiation factor-4E in superficial and muscle invasive bladder cancer and its correlation with vascular endothelial growth factor expression and tumour progression. Br J Cancer 2000;82:161-166.
44. Rosenwald IB, Hutzler MJ, Wang S, Savas L, Fraire AE: Expression of eukaryotic translation initiation factors 4E and 2alpha is increased frequently in bronchioloalveolar but not in squamous cell carcinomas of the lung. Cancer 2001;92:2164-2171.
45. Rosenwald IB, Wang S, Savas L, Woda B, Pullman J: Expression of translation initiation factor eIF-2alpha is increased in benign and malignant melanocytic and colonic epithelial neoplasms. Cancer 2003;98:1080-1088.
46. Imataka H, Olsen HS, Sonenberg N: A new translational regulator with homology to eukaryotic translation initiation factor 4G. EMBO J 1997;16:817-825.
47. Levy-Strumpf N, Deiss LP, Berissi H, Kimchi A: DAP-5, a novel homolog of eukaryotic translation initiation factor 4G isolated as a putative modulator of gamma interferon-induced programmed cell death. Mol Cell Biol 1997;17:1615-1625.
48. Pyrormet S, Imataka H, Gingras AC, Fukunaga R, Hunter T, Sonenberg N: Human eukaryotic translation initiation factor 4G (eIF4G) recruits mnk1 to phosphorylate eIF4E. EMBO J 1999;18:270-279.
49. Obermann EC, Junker K, Stoehr R, Dietmaier W, Zaak D, Schubert J, Hofstaedter F, Knuechel R, Hartmann A: Frequent genetic alterations in flat urothelial hyperplasias and concomitant papillary bladder cancer as detected by CGH, LOH, and FISH analyses. J Pathol 2003;199:50-57.
50. Zhang J, Zheng S, Gao Y, Rotolo JA, Xiao Z, Li C, Cheng S: A partial allelotyping of urothelial carcinoma of bladder in the Chinese. Carcinogenesis 2004;25:343-347.
51. Yamanaka S, Zhang XY, Maeda M, Miura K, Wang S, Farese RV Jr, Iwao H, Innerarity TL: Essential role of NAT1/p97/DAP5 in embryonic differentiation and the retinoic acid pathway. EMBO J 2000;19:5533-5541.
52. Henis-Korenblit S, Shani G, Sines T, Marash L, Shohat G, Kimchi A: The caspase-cleaved DAP5 protein supports internal ribosome entry site-mediated translation of death proteins. Proc Natl Acad Sci USA 2002;99:5400-5405.